All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. RAPT Therapeutics Inc - RAPT stock news. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Over the next 52 weeks, RAPT Therapeutics Inc has on average historically risen by 28.8 based on the past 2 years of stock performance. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc.
The stock is currently down 19.4 year-to-date, up 41.6 over the past 12 months, and up 127.7. stock price fell by -6.88 on the last day (Wednesday, 12th Jan 2022) from 33.16 to 30.88.During the day the stock fluctuated 10.11 from a day low at 30.84 to a day high of 33.96.The price has risen in 6 of the last 10 days, but is still down by -14.7 for this period. Factset: FactSet Research Systems Inc.2019. RAPT Therapeutics Inc (RAPT) shares closed this week 24.3 lower than it did at the end of last week.
Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. The best long-term & short-term RAPT Therapeutics share price. was incorporated in 2015 and is headquartered in South San Francisco, California.Most stock quote data provided by BATS. RAPT Therapeutics Stock Forecast, RAPT stock price prediction. and changed its name to RAPT Therapeutics, Inc. The company was formerly known as FLX Bio, Inc. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. Lets take a closer look to see what the different types of shareholders can tell us about RAPT Therapeutics. In the chart below, we can see that institutional investors have bought into the company. RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. RAPT Therapeutics has a market capitalization of US1.1b, so we would expect some institutional investors to have noticed the stock.
0 kommentar(er)
